Introduction {#sec1}
============

During acute infection, pathogenic viruses target numerous organs to facilitate replication and dissemination. The mechanisms of organ-specific control of virus infection are poorly understood.

The β-herpesvirus murine cytomegalovirus (MCMV) has coevolved with its mammalian host over millions of years, providing a paradigm of a well-adapted persistent virus that has been extensively exploited in studies of host-pathogen interactions in vivo. MCMV also provides the most tractable in vivo model for the pathogenic β-herpesvirus human cytomegalovirus (HCMV), exhibiting many parallels in terms of pathogenesis, host immunity, immune evasion, and broad tissue tropism ([@bib41]). NK cells are a key component of the innate immune response and are critical for the control of human herpesviruses, a control that has been elegantly modeled in MCMV ([@bib7; @bib8]). Importantly, however, the antiviral role of NK cells can be both cell-type and organ specific. For example, NK cell depletion preferentially increases MCMV progeny derived from endothelial cells as compared with nonendothelial cell-derived virus, and this effect is more profound in the lung versus other sites of infection ([@bib35]). Moreover, NK cells in the salivary gland, which represents a key site of MCMV persistence and dissemination, are hyporesponsive to MCMV infection ([@bib51]).

Studies in MCMV also highlight the pivotal role for cytokines such as type I interferons (IFNαβ), lymphotoxin, IL-12, and IL-18 in either inhibiting viral replication directly or regulating the development of innate and adaptive immunity ([@bib1; @bib2; @bib5; @bib30]). However, restricted expression of such cytokines in MCMV-infected tissues is observed ([@bib40]). Collectively, these data are consistent with the existence of additional antiviral effector mechanisms that counter CMV in a broad range of cells within a plethora of tissue microenvironments.

Interleukin-22 (IL-22) is an important effector cytokine in peripheral tissues. IL-22 is expressed by numerous innate and adaptive immune cells and signals through the IL-22Rα/IL-10Rβ dimeric receptor ([@bib44]). While IL-10Rβ is ubiquitously expressed, IL-22Rα expression is restricted to nonhematapoetic cells, with elevated expression in tissues such as the oral/gastrointestinal tract, lung, skin, kidney, and liver ([@bib56]).

IL-22 contributes to the immune control of gram-negative bacterial infections at mucosal surfaces while also exhibiting tissue-protective functions ([@bib3; @bib57; @bib59]). The role of IL-22 in viral infections is less well defined. IL-22 neutralization does not impair protection from influenza infection in mice ([@bib14]) and, in certain viral infection models, can heighten inflammation without influencing virus clearance ([@bib58]). In contrast, IL-22 is cytoprotective in the liver during arenavirus chronicity ([@bib32]). CD161^+^ T cells that express IL-22 are enriched in the liver during chronic hepatitis C virus (HCV) infection ([@bib6; @bib22]), and the single nucleotide polymorphism IL-22-rs1012356 SNP is associated with protection from HCV ([@bib16]). IL-22 has also been implicated in direct inhibition of dengue virus replication ([@bib13]) and T cell-mediated protection from horizontal HIV transmission ([@bib29]). Consequently, a consensus is beginning to emerge that IL-22 may exert antiviral control during infection.

To investigate this, we utilized the MCMV model to elucidate the role that IL-22 plays in viral infection of peripheral tissue. Our results reveal a previously unanticipated mechanism through which IL-22 impacts on virus-induced immune responses and a potent effector mechanism that counters herpesvirus infection.

Results {#sec2}
=======

IL-22 Affords Tissue-Restricted Protection from MCMV Infection {#sec2.1}
--------------------------------------------------------------

During primary infection, MCMV targets multiple organs of the secondary lymphoid tissue (e.g., spleen), mucosa (e.g., lung), and nonmucosa (e.g., liver). IL-22R mRNA is expressed predominantly in barrier surfaces and also in the liver ([@bib56]). In accordance, IL-22R was expressed in murine lung and liver, and expression was further elevated in the liver and, to a lesser extent, the lung in response to MCMV ([Figure 1](#fig1){ref-type="fig"}A). No significant IL-22R expression was detected in the spleen before or after MCMV infection ([Figure 1](#fig1){ref-type="fig"}A). Histological analysis of mice expressing LacZ under the control of the *Il-22ra1* promoter demonstrated IL-22R expression within the lung, particularly by epithelial cells (see [Figure S1](#app2){ref-type="sec"} available online). Moreover, IL-22R expression by cells with large nuclei, indicative of hepatocytes, was detectable throughout the liver ([Figure S1](#app2){ref-type="sec"}).

Given that IL-22R was expressed in mucosal and hepatic sites targeted by MCMV, we hypothesized that IL-22 influenced the outcome of acute infection. To test this, MCMV-infected mice were treated with either an IL-22-blocking antibody (αIL-22) or IgG control. IL-22 neutralization markedly increased infectious virus load in the liver as early as 2 days after infection ([Figure 1](#fig1){ref-type="fig"}B). In the lung, low levels of virus infection occur within the first 2 days of infection, as demonstrated by detection of infectious virus in only four of ten IgG-treated mice ([Figure 1](#fig1){ref-type="fig"}C). After αIL-22 treatment, however, virus was detected in eight of ten lungs, seven of which demonstrated higher virus load than IgG-treated mice ([Figure 1](#fig1){ref-type="fig"}C), highlighting an antiviral function for IL-22 during initial infection and suggesting it sets a threshold for acute virus replication in the lung. Consistent with low IL-22R expression in the spleen ([Figure 1](#fig1){ref-type="fig"}A), IL-22 neutralization did not influence virus replication in this organ ([Figure 1](#fig1){ref-type="fig"}D). Despite this tissue-restricted antiviral role for IL-22, the global effect of IL-22 was demonstrated by exacerbated weight loss in αIL-22-treated mice ([Figure 1](#fig1){ref-type="fig"}E). Thus, IL-22 limits MCMV infection in an organ-specific manner that is determined by IL-22R expression, and restricts clinical signs of virus-induced disease.

Conventional NK Cells, NK T Cells, and T Cells Are Significant Sources of IL-22 in MCMV Infection {#sec2.2}
-------------------------------------------------------------------------------------------------

MCMV infection enhanced IL-22 production in the liver and lung ([Figure 2](#fig2){ref-type="fig"}A). Conventional NK1.1^+^ NK cells and NK T cells secrete IL-22 in virus infections ([@bib14; @bib21; @bib25]), and NK1.1 depletion during MCMV infection abrogated IL-22 protein production in the liver and lung ([Figure 2](#fig2){ref-type="fig"}A). Furthermore, T cells produce IL-22 in certain infections ([@bib44]), and codepletion of CD4^+^ and CD8^+^ cells (which includes CD4^+^ NK T cells) also reduced IL-22 production ([Figure 2](#fig2){ref-type="fig"}A). NK1.1 or CD4/CD8 depletion reduced IL-22 protein concentrations below those detected in naive tissue. This may reflect higher IL-22 turnover upon infection due to increased IL-22R expression ([Figure 1](#fig1){ref-type="fig"}A) and/or possible secretion of IL-22 binding protein that, after depletion of IL-22^+^ cells, reduced detectable soluble IL-22 below levels measured in naive tissue.

In accordance with the hypothesis that NK cells, NK T cells, and CD4^+^ and CD8^+^ αβ T cells produce IL-22, analysis of cytokine secretion by leukocytes following ex vivo stimulation with PMA/ionomycin and IL-23 identified NK cells ([Figures 2](#fig2){ref-type="fig"}B--2E, [S2](#app2){ref-type="sec"}A, and S2B), CD4^+^CD3^+^, and CD8^+^CD3^+^ ([Figures 2](#fig2){ref-type="fig"}B, 2C, [S2](#app2){ref-type="sec"}A, and S2C) to be significant IL-22^+^ cells in the liver and lung, and NK T cells (NK1.1^+^CD3^+^) also representing a significant hepatic IL-22-secreting cell ([Figures 2](#fig2){ref-type="fig"}B and 2C). NK cells were the predominant IL-22^+^ cell-type at day 2 ([Figure S2](#app2){ref-type="sec"}A) and day 4 p.i. ([Figures 2](#fig2){ref-type="fig"}B and 2C). Thus, NK1.1^+^ cells and T cells represent the major IL-22-producing cells in tissues where IL-22 restricts MCMV.

Phenotypic characterization of NK cells demonstrated that, unlike NKp46^+^CD3^−^ IL-22 producing innate lymphoid cells (ILCs) of the gastrointestinal tract ([@bib39]), IL-22^+^ NK cells in the liver and lung did not express RORγT ([Figure 2](#fig2){ref-type="fig"}E). Moreover, pulmonary and hepatic IL-22^+^ NK cells expressed granzyme B, many of which coexpressed IFN-γ, suggesting conventional NK cell function ([Figure S2](#app2){ref-type="sec"}D). Indeed, a significant proportion of IL-22^+^ NK cells coexpressed CD27 and CD11b ([Figures S2](#app2){ref-type="sec"}E and S2F), indicating high cytotoxic capacity ([@bib15]). Addition of IL-23, the receptor for which is not expressed by conventional NK cells ([@bib9]), did not increase IL-22^+^ NK cell frequency detected after incubation with PMA/ionomycin ([Figure S2](#app2){ref-type="sec"}G). Also, IL-22^+^ NK cells expressed markers of conventional NK cells but not a marker of ILCs, CD127 ([Figures 2](#fig2){ref-type="fig"}F, [S2](#app2){ref-type="sec"}E, and S2F). IL-22^+^ (and IL-22^−^) NK cells upregulated the activation marker CD69 upon infection ([Figures 2](#fig2){ref-type="fig"}F and [S2](#app2){ref-type="sec"}F). Interestingly, IL-22^+^ and IL-22^−^ NK cells expressed comparable levels of the activating receptor Ly49H, suggesting the development of IL-22^+^ NK cells was not influenced by Ly49H activation.

IL-22 Promotes Accumulation of Neutrophils in Peripheral Tissue {#sec2.3}
---------------------------------------------------------------

The mechanisms through which IL-22 exerted antiviral control were next investigated. Preincubation of an IL-22R-expressing epithelial cell line (SGC1) with IL-22 did not inhibit MCMV replication (data not shown). Moreover, αIL-22 did not influence antiviral IFN (type I and II), lymphotoxin, TNF-α, IL-18, IL-1β, or IL-6 expression, nor did it influence serum amyloid A (SAA) secretion in livers and lungs day 2 p.i. (data not shown); the time point at which IL-22 first displayed antiviral activity. NK cell accumulation and ex vivo degranulation and IFN-γ expression in the lung and liver were unaltered after αIL-22 treatment (data not shown). Moreover, macrophage and monocyte accumulation within MCMV-infected organs was unaffected by αIL-22 treatment ([Figures 3](#fig3){ref-type="fig"}A--3C).

Strikingly, however, accumulation of neutrophils, which represented a substantial proportion of the MCMV-elicited leukocyte infiltrate in the liver ([Figure 3](#fig3){ref-type="fig"}D) and lung ([Figure 3](#fig3){ref-type="fig"}E) 2 days p.i., was substantially reduced in both organs after IL-22 neutralization ([Figures 3](#fig3){ref-type="fig"}A, 3B, 3D, and 3E). In the spleen, however, αIL-22 did not influence neutrophil accumulation in this IL-22-refractory site ([Figures 3](#fig3){ref-type="fig"}C and 3F).

Murine CXCL1 (KC) is the main neutrophil-activating chemokine ([@bib36]), and in vivo administration of an αCXCL1 neutralizing antibody restricted neutrophil accumulation in the liver ([Figure 3](#fig3){ref-type="fig"}G) and lung ([Figure 3](#fig3){ref-type="fig"}H). In contrast, αCXCL1 increased neutrophil accumulation in the spleen ([Figure 3](#fig3){ref-type="fig"}I), consistent with the hypothesis that neutrophil migration into the lung and liver is controlled by different mechanisms to those in the spleen. IL-22 induced secretion of CXCL1 by IL-22R^+^ SGC1 cells by 6 hr poststimulation ([Figure 3](#fig3){ref-type="fig"}J), and crucially, αIL-22 reduced CXCL1 protein concentrations in the liver ([Figure 3](#fig3){ref-type="fig"}K) and lung ([Figure 3](#fig3){ref-type="fig"}L) 2 days p.i., suggesting that early induction of CXCL1 secretion by IL-22 is critical for chemokine-driven neutrophil recruitment. Consistent with the low IL-22R expression in the spleen ([Figure 1](#fig1){ref-type="fig"}A), αIL-22 did not influence CXCL1 secretion in this organ ([Figure 3](#fig3){ref-type="fig"}M).

Neutrophils Afford Protection from MCMV Replication In Vivo {#sec2.4}
-----------------------------------------------------------

The association between the tissue-restricted antiviral activity of IL-22 and neutrophil infiltration implied an antiviral function for this cell population. Upon MCMV infection, neutrophils were detected in high numbers in infected tissues ([Figures 3](#fig3){ref-type="fig"}A--3C), and a high frequency of activated CD11b^+^ cells was present in these infected organs ([Figure 4](#fig4){ref-type="fig"}A), demonstrating that these cells were activated during MCMV infection. Furthermore, histological analysis of MCMV-infected tissue demonstrated that neutrophils localized adjacent to infected cells ([Figure 4](#fig4){ref-type="fig"}B).

To test whether neutrophils contributed to antiviral immunity, MCMV-infected mice were administered with a Ly6G-specific monoclonal antibody that specifically depleted neutrophils without affecting inflammatory monocyte/macrophage populations ([Figure 5](#fig5){ref-type="fig"}A). Strikingly, antibody-mediated depletion of neutrophils increased MCMV-induced weight loss ([Figure 5](#fig5){ref-type="fig"}B). This exacerbation of virus-induced illness was associated with elevated virus load in liver ([Figure 5](#fig5){ref-type="fig"}C) and lungs ([Figure 5](#fig5){ref-type="fig"}D), but not the spleen ([Figure 5](#fig5){ref-type="fig"}E).

C57BL/6 mice lacking adaptive immunity control acute MCMV infection, a process mediated in part by Ly49H-expressing NK cells recognizing MCMV m157 protein ([@bib11]). Strikingly, we observed that depletion of neutrophils in MCMV-infected *RAG*^−/−^ mice triggered dramatic weight loss ([Figure 5](#fig5){ref-type="fig"}F) and a concurrent large elevation in replicating virus in the livers ([Figure 5](#fig5){ref-type="fig"}G) and lungs ([Figure 5](#fig5){ref-type="fig"}H). Interestingly, in this model where ∼14% of splenocytes prior to MCMV infection are Ly6G^+^ neutrophils, depletion of these cells also increased replicating virus detected in the spleen ([Figure 5](#fig5){ref-type="fig"}I). Thus, neutrophils are critical early antiviral effector cells during CMV infection in vivo.

Neutrophils Directly Inhibit MCMV Replication {#sec2.5}
---------------------------------------------

We characterized the mechanistic control of MCMV by neutrophils. Neutrophil crosstalk with NK cells promotes NK cell development, including enhanced NK cell cytotoxicity ([@bib18]). However, as mentioned earlier, the accumulation of cytotoxic NK cells was not affected by αIL-22 (data not shown), and neutrophil depletion did not impair NK cell accumulation, cytotoxicity or IFN-γ expression ([Figure S3](#app2){ref-type="sec"}). Furthermore, concurrent depletion of both neutrophils and NK cells exhibited an additive antagonistic effect on host control of infection ([Figure 6](#fig6){ref-type="fig"}A). Of note, NK depletion did not influence neutrophil accumulation in infected tissues (data not shown). Taken with the observations that T cells secrete IL-22 ([Figures 2](#fig2){ref-type="fig"}A--2C) and that MCMV replication (which is elevated after NK1.1 depletion in this model \[[@bib45]\]) directly induces CXCL1 production ([Figure 3](#fig3){ref-type="fig"}J), these results demonstrate that NK1.1^−^ cells are capable of promoting neutrophil recruitment in the absence of NK cells. Importantly, these results also imply that neutrophil activation of NK cells is not the primary mechanism through which neutrophils control MCMV.

We investigated whether neutrophils were capable of direct antiviral activity. Coincubation of purified neutrophils ([Figure 6](#fig6){ref-type="fig"}B) with 3T3 fibroblasts led to ∼50% neutrophil viability for up to 72 hr and, interestingly, we observed a trend in elevated neutrophil viability following coincubation with MCMV-infected cells ([Figure 6](#fig6){ref-type="fig"}C). Crucially, neutrophil coincubation with MCMV-infected fibroblasts dramatically reduced the production of replicative virions in a cell-number-dependent manner ([Figure 6](#fig6){ref-type="fig"}D), demonstrating that neutrophils directly inhibit MCMV replication.

Neutrophils Exert Anti-MCMV Activity in a TRAIL-Dependent Manner {#sec2.6}
----------------------------------------------------------------

To identify the mechanism(s) through which neutrophils exert antiviral activity, expression of putative antiviral effector molecules by hepatic neutrophils isolated 2 days p.i. was measured. We detected no expression of type I and II interferons, perforin, and lymphotoxin by MCMV-induced neutrophils ([Figure S4](#app2){ref-type="sec"}A). However, MCMV-induced neutrophils expressed significant iNOS, TNF-α, TRAIL, and low but reproducibly detectable FasL mRNA ([Figure S4](#app2){ref-type="sec"}A). Gene expression analysis in whole tissue revealed that all four genes were upregulated upon MCMV infection in vivo ([Figure 7](#fig7){ref-type="fig"}A).

The effect of antagonizing each of these molecules on antiviral neutrophil activity was next assessed. Strikingly, inhibition of the death receptor ligand TRAIL dramatically abrogated the antiviral activity of neutrophils ([Figure 7](#fig7){ref-type="fig"}B) without influencing neutrophil survival ([Figure S4](#app2){ref-type="sec"}B). In addition, FasL blockade moderately antagonized neutrophil-mediated control of MCMV, although this was not statistically significant ([Figure 7](#fig7){ref-type="fig"}B). Further, soluble TRAIL ([Figure 7](#fig7){ref-type="fig"}C) and, to a lesser extent, soluble FasL ([Figure 7](#fig7){ref-type="fig"}D) inhibited MCMV replication, further implying a dominant role for TRAIL in facilitating neutrophil-mediated antiviral control. Indeed, TRAILR (DR5) was upregulated by MCMV-infected fibroblasts in vitro 6 hr p.i., although expression was downregulated by 24 hr with complete reversal of TRAILR expression by 48 hr ([Figure 7](#fig7){ref-type="fig"}E). In contrast, we observed no significant regulation of Fas by MCMV (data not shown). Collectively, these results pointed toward a dominant role for TRAIL in the anti-MCMV function of neutrophils and are consistent with the observation that CMVs actively downregulate surface TRAILR expression ([@bib43]). Furthermore, in accordance with complete downregulation of TRAILR expression by 48 hr, delaying the addition of neutrophils ([Figure 7](#fig7){ref-type="fig"}F) or soluble TRAIL ([Figure S4](#app2){ref-type="sec"}C) to MCMV-infected fibroblasts until this time point abrogated antiviral activity.

We next investigated whether TRAIL expression by neutrophils contributed to antiviral control in vivo. In accordance with infection-induced TRAIL mRNA expression ([Figure 7](#fig7){ref-type="fig"}A), MCMV induced cell-surface TRAIL expression by neutrophils ([Figure 7](#fig7){ref-type="fig"}G). We inhibited TRAIL/TRAILR interactions in vivo with blocking αTRAIL antibody in NK-depleted *RAG*^−/−^ mice, thus lacking both TRAIL-expressing NK cells and elevated NK cell responsiveness observed in *TRAILR*^−/−^ mice ([@bib10]) and in αTRAIL-treated *RAG*^−/−^ mice (data not shown). Although NK cell depletion impairs leukocyte recruitment in livers of *RAG*^−/−^ mice ([@bib38]), Ly6G depletion experiments demonstrated that neutrophils clearly exerted antiviral control ([Figure 7](#fig7){ref-type="fig"}H). Importantly, TRAIL blockade increased MCMV burden to comparable levels measured in neutrophil-depleted mice ([Figure 7](#fig7){ref-type="fig"}H). Critically, antagonizing both TRAIL and neutrophils did not further abrogate antiviral protection ([Figure 7](#fig7){ref-type="fig"}H), providing evidence that neutrophils limit MCMV replication in vivo via TRAIL. Finally, neutralization of IL-22 in neutrophil-depleted WT mice failed to further increase virus load as compared to αLy6G treatment alone, suggesting that IL-22 exerts antiviral control via neutrophil recruitment ([Figure 7](#fig7){ref-type="fig"}I). Consistent with this hypothesis, IL-22 neutralization, which resulted in an ∼2-fold reduction in neutrophil recruitment, had a lesser impact on antiviral control than Ly6G depletion ([Figure 7](#fig7){ref-type="fig"}I). Collectively, these results demonstrate that IL-22 drives antiviral neutrophil response in vivo, and that TRAIL is a significant mechanism through which neutrophils restrict MCMV replication.

Discussion {#sec3}
==========

We identified neutrophils as potent antiviral effector cells that restrict CMV infection of peripheral tissue and exert antiviral activity via TRAIL. In addition, we identified IL-22 as an important component of the antiviral immune response that recruits neutrophils to peripheral sites of MCMV infection in which IL-22R is expressed. Thus, the IL-22-neutrophil axis represents a pathway that counteracts virus invasion of peripheral tissues.

The role that neutrophils play in viral infections is not well appreciated. Depletion of Ly6G^+^ cells during influenza infection revealed that neutrophils limit influenza-induced illness, although it is not clear whether neutrophils directly impinge on virus replication ([@bib48; @bib49]). Paradoxically, neutrophils are associated with influenza-induced inflammation ([@bib26]), particularly during infection with highly pathogenic strains ([@bib34]). In contrast to MCMV, neutrophils support West Nile virus replication, while depletion experiments suggested that neutrophils exert antiviral control during later stages of acute infection ([@bib4]). Moreover, neutrophil extracellular traps capture HIV and promote virus killing via myeloperoxidase and α-defensin ([@bib37]) and limit poxvirus infection in vivo ([@bib20]). Neutrophils also kill HIV-infected CD4^+^ T cells via antibody-dependent cellular cytotoxicity ([@bib42]). Intriguingly, in the context of herpesviruses, neutropenia has been identified as a risk factor for occurrence of herpesvirus infections in immune-suppressed individuals ([@bib19; @bib27]). Importantly, depletion in mice of cells expressing Gr1, which is expressed by numerous cells including Ly6G^+^ neutrophils ([@bib48]), elevates HSV replication in the genital mucosa ([@bib28]) and cornea ([@bib53]). We now provide definitive evidence that neutrophils directly inhibit replication of a pathogenic herpesvirus in vitro and in vivo.

Expression of TRAIL is one mechanism through which neutrophils exert direct antiviral activity in vitro and in vivo. Neutrophils expressed TRAIL on the cell surface, although our data do not preclude the possibility that neutrophils also secrete TRAIL in response to MCMV. HCMV UL141 protein promotes intracellular retention of TRAIL receptors, desensitizing cells to TRAIL-mediated apoptosis ([@bib43]). We observed TRAILR downregulation in MCMV-infected fibroblasts, consistent with the role of MCMV m166 protein in restricting TRAILR expression (C.A.B, unpublished data). Abrogation of neutrophil- and TRAIL-mediated inhibition of MCMV replication after 24 hr suggests neutrophils limit virus replication within the first hours of infection when TRAILR is present on the cell surface. TRAILR downregulation implies viral evasion of TRAIL-induced cell death. However, TRAILR signaling also induces NF-κB-mediated proinflammatory cytokine production ([@bib47]), suggesting that TRAIL may induce multiple antiviral pathways. Incomplete reversal of neutrophil antiviral activity following TRAIL inhibition suggests additional mechanisms exist through which neutrophils restrict MCMV. Neutrophil exposure to MCMV or infected cells did not upregulate reactive oxygen species (data not shown), and iNOS, IFNs, iNOS, and TNF-α did not participate singularly in neutrophil antiviral activity. Instead, inhibition of FasL moderately inhibited antiviral function, suggesting neutrophils restrict MCMV via expression of TNFSF proteins.

Neutrophils receive activation signals during migration into inflamed tissue ([@bib12]), suggesting their activation in MCMV infection may be independent of virus recognition. Indeed, TRAIL expression by neutrophils is rapidly induced by IFNs ([@bib24; @bib50]). Although neutralization of individual IFNs did not abrogate anti-MCMV neutrophil activity in vitro, it is possible that multiple antiviral cytokines induce antiviral neutrophil activity in vivo without the requirement for pattern recognition receptor-mediated neutrophil activation.

IL-22R expression determined the tissue-restricted influence of IL-22 on antiviral immunity. However, neutrophil depletion in WT mice also uncovered an organ-restricted antiviral role for neutrophils, with no obvious role for neutrophils in splenic MCMV infection. CXCL1 did not influence neutrophil accumulation within the spleen. Differences in orchestration of splenic versus pulmonary and hepatic neutrophil responses may influence their ability to counter MCMV. MCMV cell tropism within different organs may also influence neutrophil antiviral control. Stromal cells are targeted by MCMV in the spleen ([@bib17; @bib40; @bib55]), and responsiveness of these cells to effector molecules produced by neutrophils may differ from infected cells in the liver and lung. Moreover, the efficiency of viral evasion mechanisms may vary in different cell types, influencing the efficacy of neutrophil antiviral control. Importantly, however, neutrophil depletion in *RAG*^−/−^ mice elevated splenic virus load, demonstrating that neutrophils can limit MCMV infection in the spleen when present in large numbers.

Given the antiviral role of neutrophils, it is surprising that HCMV encodes a homolog of the neutrophil-attractant chemokine CXCL1 (UL146), hypothesized to promote neutrophil recruitment to facilitate HCMV dissemination ([@bib33]). Host survival in acute infection is essential for establishment of virus persistence and dissemination. Thus, neutrophil limitation of acute infection facilitated by UL146 may be a necessary evil to enable virus chronicity and transmission. Alternatively, UL146 may act preferentially in certain contexts, for example by promoting neutrophil adherence to virus-infected vascular endothelium, but exert less influence within peripheral organs where, as demonstrated in MCMV infection, mammalian CXCL1 is expressed at biologically significant levels. Importantly, MCMV did not productively replicate within neutrophils ([Figure S4](#app2){ref-type="sec"}D). Moreover, we detected very few neutrophils in the salivary glands at the onset of virus persistence (data not shown), supporting the hypothesis that monocytes rather than neutrophils disseminate MCMV ([@bib46]). Given that CXCL1 promotes recruitment of nonneutrophils ([@bib52]), our data imply that UL146 may have a function distinct from neutrophil recruitment.

Of note, MCMV-infected *IL-22R*^−/−^ mice did not exhibit heightened virus load, reduced neutrophil recruitment, or CXCL1 protein in peripheral sites of infection (data not shown). Numerous cytokines can induce proinflammatory chemokines, and heightened proinflammatory cytokine and chemokine responses have been reported following viral infection of *IL-22*^−/−^ mice ([@bib13]), suggesting that alternate proinflammatory/antiviral mechanisms compensate for the absence of the IL-22R signaling in knockout mice, whereas such compensatory mechanisms are absent after IL-22 neutralization in WT mice.

Although NK1.1 depletion revealed that NK and NK T cells secrete virus-induced IL-22, concurrent depletion of NK cells and neutrophils had an additive effect on elevating virus load. Moreover, we observed no decrease in neutrophil recruitment after NK cell depletion (data not shown). Although IL-22-producing T cells in part compensate for the absence of IL-22^+^NK1.1^+^ cells, MCMV itself is a potent inducer of CXCL1 secretion. This suggests that high virus load after NK cell depletion not only induces significant pathology ([@bib54]) but also is sufficient to promote neutrophil recruitment. Thus, through interactions with the stromal compartment, NK cells may promote *controlled* neutrophil recruitment by restricting virus replication *and* inducing IL-22-dependent neutrophil-activating chemokines.

IL-22 neutralization in neutrophil-depleted mice failed to further increase virus load, suggesting a dominant role of neutrophil recruitment in the antiviral activity of IL-22. However, our study does not preclude the existence of additional antiviral pathways elicited by IL-22R signaling. IL-22 exerts a vast range of biological activities ([@bib31; @bib44; @bib57]). Indeed, during HIV and influenza infections, IL-22 limits epithelial cell damage at mucosal surfaces ([@bib23; @bib25]). Given the critical role of mucosal surfaces in herpesvirus dissemination and pathogenesis, the role that IL-22 may play in acute and chronic infection of the mucosa warrants further investigation.

In summary, we identify IL-22 as a critical antiviral effector cytokine in peripheral sites of MCMV infection and identified the recruitment of neutrophils as a mechanism through which IL-22 affords antiviral protection. These data define neutrophils as an important antiviral effector cell population that acts during the initial stages of CMV infection and uncover the TRAIL/TRAILR pathway as a mechanism through which neutrophils exert antiviral control.

Experimental Procedures {#sec4}
=======================

Mice, Viral Infections, and Treatments {#sec4.1}
--------------------------------------

All experiments were conducted under a UK Home Office project license (PPL 30/2442 and 30/2969). WT C57BL/6 mice were purchased (Harlan), *RAG1*^−/−^ mice were bred in-house, *IL-22*^−/−^ mice were kindly provided by Jean-Christophe Renauld (Ludwig Institute, Brussels), and IL-22RA1 reporter mice were generated as described in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}. MCMV Smith strain (ATCC) was prepared in BALB/c salivary glands and purified over a sorbital gradient. Virus from homogenized organs and tissue culture supernatants were titered on 3T3 cells. Mice were infected intraperitoneally (i.p.) with 3 × 10^4^ pfu MCMV and weighed daily. Some mice were injected i.p. with 200 μg αNK1.1 (clone PK136, BioXCell) or IgG control on days −2, 0, and +2 p.i. For T cell depletion, mice were injected (i.p.) with 200 μg αCD4 antibody (100 μg clone YTS191, 100 μg clone YTS3) and 200 μg αCD8 antibody (100 μg clone YTS156, 100 μg clone YTS169, all in-house). Neutrophils were depleted with 100 μg αLy6G (clone 1A8, BioXCell); for TRAIL neutralization mice were administered 250 μg of αTRAIL (clone N2B2, Biolegend), and for IL-22 neutralization mice were administered i.v. 50 μg goat IgG (Chemicon) or αIL-22 (R&D Systems). Some mice were treated with 100 μg IgG or αCXCL1 (clone 124014, R&D Systems). All administrations were day 0 and, for 4-day experiments, 2 p.i.

Flow Cytometry {#sec4.2}
--------------

Leukocytes were isolated from murine tissue as previously described ([@bib45]) and stained with Live/Dead Fixable Aqua (Invitrogen), incubated with Fc block (eBioscience), and stained for surface markers with a combination of antibodies listed in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}. To detect IL-22-secreting cells, cells were incubated in brefeldin A (Sigma-Aldrich) ± IL-23 (50 μg/ml, R&D Systems) ± 50 ng/ml PMA and 500 ng/ml ionomycin (both Sigma-Aldrich) prior to surface staining and permeabilization with saponin buffer, stained with αIL-22, αIFN-γ, αgranzyme B, and/or αRORγT. To measure CD11b expression by neutrophils, tissues remained on ice during processing and red blood cells were not lysed, to avoid cell stimulation prior to staining. For TRAILR expression analysis, fibroblasts were infected with MCMV at a moi of 0.2 and stained with αTRAILR (clone 5D5-1, eBioscience). Further details are provided in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Cytokine/Chemokine Protein Measurement {#sec4.3}
--------------------------------------

Excized lungs, livers, and spleens (∼50 mg) were weighed, washed in PBS, and homogenized in DMEM. Supernatants were assayed for cytokines by cytometric bead array (eBioscience) or, for IL-22 and CXCL1, ELISA (eBioscience and R&D Systems, respectively). In some experiments, 3T3 fibroblasts and SGC1 cells (determined by FACS to be IL-22R^−^ and IL-22R^+^, respectively, data not shown) were infected with MCMV (moi 0.5) or treated with 50 ng/ml IL-22 (R&D Systems) for 30 min prior to washing. CXCL1 protein was assayed by ELISA after 6 hr.

Histological Analysis {#sec4.4}
---------------------

To identify IL-22RA^+^ cells, tissue sections from WT and *IL-22ra1*-LacZ mice were stained overnight in 0.1% (w/v) 5-bromo-4-chloro-3-indolyl-beta-D-galactosidase (X-gal; Invitrogen), and reporter activity identified under light microscopy (Zeiss Axiovert 200M) with AxioVision version 4.8.2 software. Neutrophil colocalization was assessed in paraffin-embedded liver sections stained with αm123 and αLy6G and visualized with DAB (Vector Labs) and VIP Chromogen solution (Vector Labs), respectively. Further details are in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Assessment of Gene Expression {#sec4.5}
-----------------------------

RNA was extracted from tissue by RNA easy kit (QIAGEN), cDNA synthesized with a TaqMan reverse transcription kit (Applied Biosystems), and gene expression determined by quantitative PCR using a Mini Opticon (Bio-Rad) and Platinum SYBR green mastermix reagent (Biorad), using primers listed in [Table S1](#app2){ref-type="sec"}.

Assessment of Neutrophil Antiviral Activity {#sec4.6}
-------------------------------------------

Splenic neutrophils were purified from *RAG*^−/−^ mice using a negative selection kit (Stemcell technologies) and a positive selection kit (Miltenyi Biotec) as described in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}, and incubated with MCMV-infected 3T3s (moi 0.02). MCMV in supernatants was measured 7 days later by plaque assay. Freeze-thawed neutrophils were nonviable controls. Some wells received inhibitory reagents: αTRAIL (10 μg/ml, clone N2B2, Biolegend), αFasL (10 μg/ml, clone 101626, R&D Systems), αIFNα (10 μg/ml, clone RMMA-1, PBL Interferon Source), αIFNβ (10 μg/ml, clone RMMB-1, PBL Interferon Source), αIFNγ (10 μg/ml, clone XMG1.2, in house), αTNF-α (10 μg/ml, XT22, in house), and iNOS inhibitors (10 μM, 1400W, Sigma-Aldrich). Some MCMV-infected fibroblasts were treated with TRAIL or FAS (R&D Systems) at concentrations stated in [Figure 7](#fig7){ref-type="fig"}.

Statistics {#sec4.7}
----------

Statistical significance was determined using the Mann-Whitney *U* test (viral load analysis) or the two-tailed Student's t test (weight loss, flow cytometry, ELISA); ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.001.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S4, Table S1, and Supplemental Experimental ProceduresDocument S2. Article plus Supplemental Information
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![IL-22 Limits Acute MCMV Replication in a Tissue-Restricted Manner\
(A) IL-22R gene expression in the liver, lungs, and spleens of naive (day 0) and MCMV-infected mice day 2 p.i.\
(B--D) Replicating virus in livers (B), lungs (C), and spleens (D) of mice infected for 2 (triangles) and 4 (circles) days and treated with IgG or αIL-22. Results are expressed as PFU/g tissue. Individual mice + median values are shown. Dotted line, limit of detection (LD).\
(E) Weight loss is expressed as mean ± SEM (6 mice/group) of percent of starting weight. Data represent two to six experiments. See also [Figure S1](#app2){ref-type="sec"}.](gr1){#fig1}

![Conventional NK Cells, NK T Cells, and αβ T Cells Express IL-22 during MCMV Infection\
(A--C) Mice were infected with MCMV or mock infected (naive), and day 4 p.i. liver (left) and lung (right) tissue was isolated. (A) IL-22 protein concentrations within organ homogenates from naive mice, MCMV-infected mice (day 4 p.i.) treated with IgG, αNK1.1, or αCD4 and αCD8. (B and C) The proportion (B) and total numbers (C) of IL-22^+^ cells in naive and infected (day 4 p.i.) organs were assessed by FACS. Results show mean ± SEM of four to seven mice/group and represent two (A) or six (B and C) experiments studying expression at either day 2 or day 4 p.i.\
(D) Representative bivariate flow cytometry plots of IL-22 versus NK1.1 expression by hepatic NK1.1^+^CD3^+^ cells from WT (left and middle) or *IL-22*^−/−^ mice day 0 or day 4 p.i., measured after 4 hr stimulation with PMA/ionomycin.\
(E) Expression of RORγT by NK1.1^+^CD3^−^IL-22^+^ cells derived from the Peyer's patch (PP), liver and lung, and splenic CD3^+^ cells from naive mice.\
(F) Representative histogram overlays of surface marker expression by IL-22^+^ (solid line) and IL-22^−^ (dotted line) pulmonary NK cells day 0 and day 4 p.i. Results represent ≥3 experiments. See also [Figure S2](#app2){ref-type="sec"}.](gr2){#fig2}

![IL-22 Neutralization Impairs Neutrophil Recruitment into MCMV-Infected Tissues\
MCMV-infected mice were administered IgG or αIL-22 and leukocyte infiltrates (A--F) and chemokine protein expression (K--M) assessed after 2 days. Myeloid cell numbers in liver (A), lung (B), and spleen (C) were quantified and are shown as mean ± SEM of six mice per group. Representative bivariate plots of Ly6G^+^CD11b^+^ neutrophils in the liver (D), lung (E), and spleen (F). Results represent three experiments. (G--I) MCMV-infected mice were treated with IgG or αCXCL1 and neutrophil (Ly6G^+^CD11b^+^) recruitment into the liver (G), lung (H), and spleen (I) assessed by FACS. Results are expressed as mean + SEM of 11 mice, with data from two independent experiments combined. (J) 3T3 (IL-22R^−^) and SGC1 (IL-22R^+^) cells were incubated for 6 hr in medium alone, 50 ng/ml rIL-22, or medium alone prior to MCMV infection (moi 0.5). Supernatants were then assayed for CXCL1 protein. Data are shown as mean + SEM of duplicate samples, representing four experiments. (K--M) CXCL1 protein in liver (K), lung (L), and spleen (M) homogenates from IgG- or αIL-22-treated mice day 2 p.i. Mean + SEM of eight (naive) or ten (MCMV infected ± αIL-22) mice is shown. Results are combined from two independent experiments, representing four in total.](gr3){#fig3}

![Neutrophil Recruitment into MCMV-Infected Organs\
(A) CD11b expression by pulmonary (top) and splenic (bottom) neutrophils in infected (day 2 p.i.) or mock-infected mice.\
(B) Neutrophil localization near MCMV-infected (m123^+^) cells in the liver was visualized in hematoxylin-stained paraffin-embedded sections. Liver sections from mock-infected tissues (10×, top left) were used as negative controls for αm123 (brown) and αLy6G (purple) staining. Infected tissue is shown at 10× magnification (bottom left) and 60× (top and bottom right). All images are taken from different mice, representing \<8. Arrow, MCMV-infected m123^+^ nucleus; triangle, neutrophil. Bars, 100 μM (10× magnification), 20 μM (60× magnification).](gr4){#fig4}

![Neutrophil Depletion Impairs Control of Acute MCMV Infection\
MCMV-infected and mock-infected C57BL/6 (A--E) or *RAG1*^−/−^ (F--I) mice were treated with αLy6G or IgG. (A) Representative bivariate plots demonstrating specific depletion of neutrophils (Ly6B^int^Gr1^hi^) in lungs and livers with αLy6G antibody. (B) Weight loss in MCMV-infected and mock-infected IgG- and αLy6G-treated mice is expressed as percentage of original weight and is shown as mean ± SEM of ten mice per infected group and three mice per naive group. Replicating virus in livers (C), lungs (D), and spleens (E) 4 days p.i. in IgG- and αLy6G-treated mice is shown as individual mice + median. All data represent five independent experiments. (F--I) MCMV-infected *RAG1*^−/−^ mice were treated with IgG or αLy6G. (F) Weight loss is expressed as percentage of original weight and is shown as mean ± SEM of five mice per group, representing two experiments. (G--I) Replicating virus in homogenates from the livers (G), lungs (H), and spleens (I) 4 days p.i. in IgG- and anti-Ly6G-treated *RAG*^−/−^ mice. Individual mice + median from two experiments are shown.](gr5){#fig5}

![Neutrophils Limit MCMV Replication In Vitro\
(A) MCMV-infected mice were treated ± αLy6G ± αNK1.1, and day 4 p.i. virus load was measured by plaque assay. Data from two experiments + median are shown.\
(B--D) Neutrophil purity was assessed by FACS (B), and survival following incubation with mock-infected and MCMV-infected fibroblasts was assessed with Annexin V and live/dead aqua (C). (D) Replicating virus in supernatants from neutrophil/fibroblast cocultures was measured after 7 days. Some wells received freeze-thawed neutrophils as negative controls. Data represent three (A), two (C), and four (B and D) experiments. See also [Figure S3](#app2){ref-type="sec"}.](gr6){#fig6}

![Neutrophils Limit MCMV Replication in a TRAIL-Dependent Manner\
(A) Whole-tissue gene expression in naive and infected (day 2 p.i.) livers. (B) Purified neutrophils were added or not at a ratio of 1:1 neutrophils:infected fibroblast ± antagonists of potential antiviral effector molecules. Relative reduction in MCMV PFU was compared between medium control and experimental groups. (C and D) Infected fibroblasts were incubated with recombinant TRAIL (C) or recombinant FasL (D) and replicating virus measured after 7 days. (E) Fibroblasts were MCMV infected (moi 0.2), and TRAILR expression was measured by FACS. Shaded, FMO; dotted lines, mock infected; solid line, MCMV infected. (F) Purified neutrophils were added or not to MCMV-infected fibroblasts 0, 24, or 48 hr p.i. and virus measured 7 days later. Data are shown as mean + SEM of four replicates. (G) Representative bivariant FACS plots of surface TRAIL expression by liver neutrophils. FMO, fluorescence minus one; positive control, NK1.1^+^CD3^−^ cells from naive livers of 3-week-old mice. (H) MCMV-infected *RAG*^−/−^ mice were depleted of NK1.1 cells and administered IgG (●), αLy6G (○), αTRAIL (▪) or αLy6G and αTRAIL (□), and hepatic virus load was measured at day 4 p.i. (I) MCMV-infected C57BL/6 mice were administered IgG (●), αIL-22 (○), αLy6G (▪), or αIL-22 and αLy6G (□) and virus load in liver tissue measured 4 days p.i. Results represent two (A, C, D, F, and G) or three (B and E) independent experiments, or show data merged from two experiments (H and I). See also [Figure S4](#app2){ref-type="sec"}.](gr7){#fig7}
